Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pembrolizumab biosimilar - Qilu Pharmaceutical

Next Previous
Drug Profile

Pembrolizumab biosimilar - Qilu Pharmaceutical

Alternative Names: QL-2107

Latest Information Update: 04 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Qilu Pharmaceutical
  • Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies; Obesity therapies; Tumour-agnostic therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 24 Oct 2025 Phase-I/II clinical trials in Solid tumours (First-line therapy, Combination therapy, Late-stage disease, Metastatic disease) in China (IV)
  • 09 Sep 2025 Qilu Pharmaceutical plans a phase III trial for Non-small cell lung cancer ( Adjuvant therapy) in unknown location (IV, Infusion) in September 2025 (NCT07162883 )
  • 27 Apr 2025 Qilu Pharmaceutical plans a phase II trial for Gastric cancer (First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Combination therapy) in an unknown location (IV) (NCT06942767)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top